{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T21:33:16Z","timestamp":1774301596170,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2021J01397"],"award-info":[{"award-number":["2021J01397"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2022GGA010"],"award-info":[{"award-number":["2022GGA010"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.breast.2025.104551","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T02:23:46Z","timestamp":1754619826000},"page":"104551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical and economic research of bone modifiers as adjuvant therapy for early breast cancer: A systematic literature review"],"prefix":"10.1016","volume":"83","author":[{"given":"Wenhua","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8739-6652","authenticated-orcid":false,"given":"Yixiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2025.104551_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.breast.2025.104551_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.breast.2025.104551_bib3","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-17-0309","article-title":"The role of IL-1B in breast cancer bone metastasis","volume":"25","author":"Tulotta","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.breast.2025.104551_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/CMAR.S155524","article-title":"Bone metastasis pattern in initial metastatic breast cancer: a population-based study","volume":"10","author":"Xiong","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.breast.2025.104551_bib5","first-page":"622","volume":"43","year":"2021","journal-title":"Zhonghua zhong liu za zhi [Chinese journal of oncology]"},{"key":"10.1016\/j.breast.2025.104551_bib6","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.breast.2025.104551_bib7","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol : Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.breast.2025.104551_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.21.02647","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update","volume":"40","author":"Eisen","year":"2022","journal-title":"J Clin Oncol : Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.breast.2025.104551_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-021-06147-1","article-title":"Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey","volume":"187","author":"McGee","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104551_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100402","article-title":"Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: challenges and lessons learnt from comparison of the UK and Australian experience","volume":"31","author":"Porter","year":"2021","journal-title":"Journal of Bone Oncology"},{"key":"10.1016\/j.breast.2025.104551_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000499931","article-title":"St. Gallen\/Vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment","volume":"14","author":"Balic","year":"2019","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2025.104551_bib12","author":"Higgins"},{"key":"10.1016\/j.breast.2025.104551_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.breast.2025.104551_bib14","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.breast.2025.104551_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","article-title":"Development and validation of a grading system for the quality of cost-effectiveness studies","volume":"41","author":"Chiou","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.breast.2025.104551_bib16","first-page":"53","article-title":"Examining the value and quality of health economic analyses: implications of utilizing the QHES","volume":"9","author":"Ofman","year":"2003","journal-title":"J Manag Care Pharm: JMCP"},{"key":"10.1016\/j.breast.2025.104551_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","article-title":"Benefits and risks of adjuvant treatment with zoledronic acid in stage II\/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01\/04)","volume":"13","author":"Coleman","year":"2018","journal-title":"Journal of Bone Oncology"},{"key":"10.1016\/j.breast.2025.104551_bib18","first-page":"28","article-title":"Natural history of stage II\/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences","author":"D'Oronzo","year":"2021","journal-title":"Journal of Bone Oncology"},{"key":"10.1016\/j.breast.2025.104551_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3816\/CBC.2010.n.062","article-title":"Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer","volume":"10","author":"Leal","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2025.104551_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian breast and colorectal cancer study group trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol : Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.breast.2025.104551_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.004","article-title":"Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial","volume":"118","author":"Perrone","year":"2019","journal-title":"European Journal of Cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.breast.2025.104551_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/1471-2407-13-480","article-title":"Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial","volume":"13","author":"Banys","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2025.104551_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.05.015","article-title":"German breast Grp, A. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - the phase III NeoAdjuvant trial Add-oN (NaTaN) study (GBG 36\/ABCSG 29)","volume":"64","author":"von Minckwitz","year":"2016","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.breast.2025.104551_bib24","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1158\/0008-5472.SABCS-09-4082","article-title":"Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST","volume":"69","author":"Coleman","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2025.104551_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2025.104551_bib26","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2025.104551_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol : Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.breast.2025.104551_bib28","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jamaoncol.2021.1854","article-title":"Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial","volume":"7","author":"Friedl","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib29","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib30","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib31","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National surgical adjuvant breast and bowel project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib32","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2025.104551_bib33","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J Clin Oncol: Official Journal of the American Society of Clinical Oncology"},{"issue":"2934\u20132945","key":"10.1016\/j.breast.2025.104551_bib34","article-title":"Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer (BOOG 2006-04): randomized phase III TEAM-IIB trial","volume":"40","author":"Vliek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2018.12.005","article-title":"Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial","volume":"108","author":"Livi","year":"2019","journal-title":"European Journal of Cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.breast.2025.104551_bib36","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djz215","article-title":"Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307","volume":"112","author":"Gralow","year":"2020","journal-title":"JNCI-Journal of The National Cancer Institute"},{"key":"10.1016\/j.breast.2025.104551_bib37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/02841860801964988","article-title":"Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer","volume":"47","author":"Kristensen","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.breast.2025.104551_bib39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib41","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s12325-021-01812-9","article-title":"Bone health outcomes from the international, multicenter, randomized, phase 3, placebo-controlled D-CARE study assessing adjuvant denosumab in early breast cancer","volume":"38","author":"Coleman","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.breast.2025.104551_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3892\/ol_00000044","article-title":"Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes","volume":"1","author":"Kokufu","year":"2010","journal-title":"Oncol Lett"},{"key":"10.1016\/j.breast.2025.104551_bib43","series-title":"Evidence reviews for adjuvant bisphosphonates: early and locally advanced breast cancer: diagnosis and management: evidence review G","year":"2018"},{"key":"10.1016\/j.breast.2025.104551_bib44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3816\/CBC.2010.n.034","article-title":"Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer","volume":"10","author":"Delea","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2025.104551_bib45","first-page":"35","article-title":"Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis","author":"Huang","year":"2023","journal-title":"Int J Qual Health Care : Journal of the International Society for Quality in Health Care"},{"key":"10.1016\/j.breast.2025.104551_bib46","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.3747\/co.22.2383","article-title":"Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels","volume":"22","author":"Lamond","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000315699","article-title":"Results of the Zometa cost-utility model for the German healthcare system based on the results of the ABCSG-12 study","volume":"33","author":"Lux","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.breast.2025.104551_bib48","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol : Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.breast.2025.104551_bib49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/03008916221078062","volume":"108","author":"Gravina","year":"2022","journal-title":"Tumori"},{"key":"10.1016\/j.breast.2025.104551_bib50","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group","volume":"101","author":"Brincker","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.breast.2025.104551_bib51","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.507","article-title":"Long-term outcomes of adjuvant denosumab in breast cancer: fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebocontrolled ABCSG-18 trial","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1078155207080806","article-title":"Significance and impact of bisphosphonate-induced acute phase responses","volume":"13","author":"Olson","year":"2007","journal-title":"J Oncol Pharm Pract: Official Publication of the International Society of Oncology Pharmacy Practitioners"},{"issue":"Suppl 4","key":"10.1016\/j.breast.2025.104551_bib53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2025.104551_bib54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ctrv.2012.03.002","article-title":"Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations","volume":"38","author":"Hadji","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2025.104551_bib55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.critrevonc.2010.07.017","article-title":"Dosing of zoledronic acid throughout the treatment continuum in breast cancer","volume":"79","author":"Hadji","year":"2011","journal-title":"Crit Rev Oncol-Hematol"},{"key":"10.1016\/j.breast.2025.104551_bib56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-018-0535-z","article-title":"Adjuvant bisphosphonate therapy in postmenopausal breast cancer","volume":"19","author":"Strobl","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib58","series-title":"Early and locally advanced breast cancer: diagnosis and management","year":"2018"},{"key":"10.1016\/j.breast.2025.104551_bib59","first-page":"Cd003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O'Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.breast.2025.104551_bib60","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaoncol.2022.1059","article-title":"Effect of Denosumab added to 2 different nab-Paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer: the GeparX 2 \u00d7 2 randomized clinical trial","volume":"8","author":"Blohmer","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib61","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jnci\/djz216","article-title":"Bisphosphonate choice as adjuvant therapy for breast cancer: does it matter?","volume":"112","author":"Brufsky","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2025.104551_bib62","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2022.12.003","article-title":"Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12","volume":"180","author":"Beltran-Bless","year":"2023","journal-title":"European Journal of Cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.breast.2025.104551_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100343","article-title":"Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer","volume":"26","author":"Awan","year":"2021","journal-title":"Journal of Bone Oncology"},{"key":"10.1016\/j.breast.2025.104551_bib64","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S1470-2045(17)30603-4","article-title":"Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01\/04) trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104551_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab054","article-title":"MAF amplification and adjuvant clodronate outcomes in early-stage breast cancer in NSABP B-34 and potential impact on clinical practice","volume":"5","author":"Paterson","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.breast.2025.104551_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081898","article-title":"Definition of high-risk early hormone-positive HER2-Negative breast cancer: a consensus review","volume":"14","author":"Garutti","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2025.104551_bib67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41523-021-00286-w","article-title":"Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer","volume":"7","author":"Puglisi","year":"2021","journal-title":"NPJ Breast Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:09:21Z","timestamp":1762344561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625005685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":66,"alternative-id":["S0960977625005685"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104551","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and economic research of bone modifiers as adjuvant therapy for early breast cancer: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104551"}}